To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could lend it ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by respiratory syncytial virus due to certain ...

Based on data from its AReSVi-006 trial, the British vaccine maker said Arexvy, compared to a placebo, led to an overall ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

The study evaluated the efficacy of a single dose of its respiratory syncytial virus (RSV) vaccine, Arexvy, for protection ... The EC granted marketing authorization to mRESVIA for use in adults ...

GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy and safety of a single dose of AREXVY(Respiratory ...

Commissions do not affect our editors' opinions or evaluations. Marketing customer relationship management (CRM) platforms help businesses manage their pipelines, capture a complete view of their ...

The study evaluated the efficacy of a single dose of its respiratory syncytial virus (RSV) vaccine, Arexvy, for protection against lower respiratory tract disease (LRTD) caused by RSV in adults ...